|
1
|
Anderson CB, Philpott GW and Ferguson TB:
The treatment of malignant pleural effusions. Cancer. 33:916–922.
1974. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Memon A and Zawadzki ZA: Malignant
effusions: diagnostic evaluation and therapeutic strategy. Curr
Probl Cancer. 5:1–30. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomas JM and Musani AI: Malignant pleural
effusions: a review. Clin Chest Med. 34:459–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zebrowski BK, Yano S, Liu W, et al:
Vascular endothelial growth factor levels and induction of
permeability in malignant pleural effusions. Clin Cancer Res.
5:3364–3368. 1999.PubMed/NCBI
|
|
5
|
Brown LF, Detmar M, Claffey K, et al:
Vascular permeability factor/vascular endothelial growth factor: a
multifunctional angiogenic cytokine. EXS. 79:233–269.
1997.PubMed/NCBI
|
|
6
|
Takahama M, Tsutsumi M, Tsujiuchi T, et
al: Enhanced expression of Tie 2, its ligand angiopoietin-1,
vascular endothelial growth factor, and CD31 in human non-small
cell lung carcinomas. Clin Cancer Res. 5:2506–2510. 1999.PubMed/NCBI
|
|
7
|
Ferrara N: Vascular endothelial growth
factor: molecular and biological aspects. Curr Top Microbiol
Immunol. 237:1–30. 1999.PubMed/NCBI
|
|
8
|
Bertino EM and Otterson GA: Benefits and
limitations of antiangiogenic agents in patients with non-small
cell lung cancer. Lung Cancer. 70:233–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, Fei D, Vanderlaan M and Song A:
Biological activity of bevacizumab, a humanized anti-VEGF antibody
in vitro. Angiogenesis. 7:335–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ribeiro SC, Vargas FS, Antonangelo L, et
al: Monoclonal anti-vascular endothelial growth factor antibody
reduces fluid volumein an experimental model of inflammatory
pleural effusion. Respirology. 14:1188–1193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pichelmayer O, Zielinski C and Raderer M:
Response of a nonmalignant pleural effusion to bevacizumab. N Engl
J Med. 353:740–741. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujita A, Takabatake H, Tagaki S and
Sekine K: Combination chemotherapy in patients with malignant
pleural effusions from non-small cell lung cancer: cisplatin,
ifosfamide, and irinotecan with recombinant human granulocyte
colony-stimulating factor support. Chest. 119:340–343. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goldstraw P, Crowley J, Chansky K, et al
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnson DH, Fehrenbacher L, Novotny WF, et
al: Randomized phase II trial comparing bevacizumab plus
carboplatin and paclitaxel with carboplatin and paclitaxel alone in
previously untreated locally advanced or metastatic non-small-cell
lung cancer. J Clin Oncol. 22:2184–2191. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Musani AI: Treatment options for malignant
pleural effusion. Curr Opin Pulm Med. 15:380–387. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kitamura K, Kubota K, Ando M, et al:
Bevacizumab plus chemotherapy for advanced non-squamous
non-small-cell lung cancer with malignant pleural effusion. Cancer
Chemother Pharmacol. 71:457–461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du N, Li X, Li F, et al: Intrapleural
combination therapy with bevacizumab and cisplatin for non-small
cell lung cancer-mediated malignant pleural effusion. Oncol Rep.
29:2332–2340. 2013.PubMed/NCBI
|
|
20
|
Verheul HM, Hoekman K, Jorna AS, Smit EF
and Pinedo HM: Targeting vascular endothelial growth factor
blockade: ascites and pleural effusion formation. Oncologist.
1:45–50. 2000. View Article : Google Scholar
|
|
21
|
Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto
Y, Bando H and Sone S: Vascular endothelial growth factor in
malignant pleural effusion associated with lung cancer. Cancer
Immunol Immunother. 48:396–400. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yano S, Shinohara H, Herbst RS, et al:
Production of experimental malignant pleural effusions is dependent
on invasion of the pleura and expression of vascular endothelial
growth factor/vascular permeability factor by human lung cancer
cells. Am J Pathol. 157:1893–1903. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng D, Rodriguez RM, Perkett EA, et al:
Vascular endothelial growth factor in pleural fluid. Chest.
116:760–765. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu IL, Su WC, Yan JJ, Chang JM and Lai
WW: Angiogenetic biomarkers in non-small cell lung cancer with
malignant pleural effusion: correlations with patient survival and
pleural effusion control. Lung Cancer. 65:371–376. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yano S, Herbst RS, Shinohara H, et al:
Treatment for malignant pleural effusion of human lung
adenocarcinoma by inhibition of vascular endothelial growth factor
receptor tyrosine kinase phosphorylation. Clin Cancer Res.
6:957–965. 2000.PubMed/NCBI
|
|
26
|
Mesiano S, Ferrara N and Jaffe RB: Role of
vascular endothelial growth factor in ovarian cancer: inhibition of
ascites formation by immunoneutralization. Am J Pathol.
153:1249–1256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma X, Yao Y, Yuan D, et al: Recombinant
human endostatin endostar suppresses angiogenesis and
lymphangiogenesis of malignant pleural effusion in mice. PLoS One.
7:e534492012. View Article : Google Scholar : PubMed/NCBI
|
